University Diaries » ‘On November 9, 2020, [U. Chicago Professor Daniel] Catenacci received an email from Five Prime’s chief medical officer, … [notifying] him that [cancer drug] bemarituzamb passed its Phase 2 clinical trial and that U.S. securities law prohibited him from selling or buying stocks on the basis of this information, according to the charges. The following morning, Catenacci bought 8,743 shares of Five Prime’s stock. Five Prime publicly announced the results of the trial after the market closed that same day.’

UD at Inside Higher Ed About Margaret Soltan Other Writings Subscribe to UD's Feeds

← Previous Post: Poem. | Next Post: “His bruised ego matters more to him than our democracy or our Constitution. He can’t accept he lost.” →

‘On November 9, 2020, [U. Chicago Professor Daniel] Catenacci received an email from Five Prime’s chief medical officer, … [notifying] him that [cancer drug] bemarituzamb passed its Phase 2 clinical trial and that U.S. securities law prohibited him from selling or buying stocks on the basis of this information, according to the charges. The following morning, Catenacci bought 8,743 shares of Five Prime’s stock. Five Prime publicly announced the results of the trial after the market closed that same day.’

LOL. Bad boy. Bad, bad, boy.

Margaret Soltan, January 6, 2022 1:07AM
Posted in: conflict of interest

Trackback URL for this post:
https://www.margaretsoltan.com/wp-trackback.php?p=68602

Comment on this Entry

Search

Latest UD posts at IHE

Read more UD at IHE…

Archives

2024 (219)
2023 (733)
2022 (852)
2021 (751)
2020 (789)
2019 (753)
2018 (803)
2017 (749)
2016 (863)
2015 (861)
2014 (1052)
2013 (1019)
2012 (1187)
2011 (1399)
2010 (1372)
2009 (1450)
2007 (1)

Categories

University Diaries is powered by WordPress
Report web site problems to [email protected]